Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: trigagrelor
Drug: Clopidogrel

First Posted Date: 2012-06-22

Last Posted Date: 2014-08-28

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 125

Registration Number: NCT01626534

Locations: 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Clopidogrel

First Posted Date: 2012-06-18

Last Posted Date: 2012-06-25

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 68

Registration Number: NCT01621763

Locations: 🇮🇳
Lambda Therapeutic Research Ltd, Ahmedabad, Gujrat, India

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions

Phase 1

Completed

Conditions: Fasting

Interventions: Drug: Clopidogrel

First Posted Date: 2012-06-18

Last Posted Date: 2012-06-18

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 68

Registration Number: NCT01621750

Locations: 🇮🇳
Lambda Therapeutic Research Ltd, Ahmedabad, Gujrat, India

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Phase 4

Terminated

Conditions: Thrombosis
Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2012-06-06

Last Posted Date: 2018-04-26

Lead Sponsor: Indiana University

Target Recruit Count: 67

Registration Number: NCT01612884

Locations: 🇺🇸
Eskenazi Health, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States